COMMUNIQUÉ DE PRESSE publié le 17/05/2025 à 00:00, il y a 11 mois 23 jours Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada Onco-Innovations Limited to transfer listing of Common Shares to Cboe Canada from CSE; trading on Cboe Canada begins on May 22, 2025. Company aims for investor trust, liquidity, and visibility under existing ticker symbol 'ONCO' Common Shares Listing Transfer Onco-Innovations Limited Cboe Canada Investor Trust
BRÈVE publiée le 25/04/2025 à 00:05, il y a 1 année Onco-Innovations' Inka Health Partners with AstraZeneca Canada Real-world Evidence Onco-Innovations Inka Health AstraZeneca Canada Drug Submission
BRÈVE publiée le 25/04/2025 à 00:05, il y a 1 année Inka Health d'Onco-Innovations s'associe à AstraZeneca Canada Preuves Du Monde Réel Onco-Innovations AstraZeneca Canada Inka Santé Soumission De Médicament
COMMUNIQUÉ DE PRESSE publié le 25/04/2025 à 00:00, il y a 1 année Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science Onco-Innovations Limited's subsidiary, Inka Health Corp., partners with AstraZeneca Canada for real-world evidence research in oncology. The new engagement showcases Inka Health's expertise in evidence translation and market access Oncology Onco-Innovations Limited Inka Health Corp. AstraZeneca Canada Real-world Evidence Research
BRÈVE publiée le 18/04/2025 à 00:05, il y a 1 année Onco-Innovations Partners with Dalton Pharma for PNKP Isotope Synthesis Cancer Research Onco-Innovations PNKP Technology Dalton Pharma Services ADME Studies
BRÈVE publiée le 18/04/2025 à 00:05, il y a 1 année Onco-Innovations s'associe à Dalton Pharma pour la synthèse de l'isotope PNKP Recherche Sur Le Cancer Onco-Innovations Technologie PNKP Services Pharmaceutiques Dalton Études ADME
COMMUNIQUÉ DE PRESSE publié le 18/04/2025 à 00:00, il y a 1 année Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology Onco-Innovations partners with Dalton Pharma Services to synthesize heavy labelled PNKP inhibitor for increasing survival rate in colorectal cancer mice. Study showcases promising therapeutic potential Colorectal Cancer Survival Rate Onco-Innovations Dalton Pharma Services PNKP Inhibitor
BRÈVE publiée le 17/04/2025 à 01:35, il y a 1 année Onco-Innovations Plans $600,000 Private Placement Private Placement Warrants Regulatory Approval Securities Offering Corporate Funding
BRÈVE publiée le 17/04/2025 à 01:35, il y a 1 année Onco-Innovations prévoit un placement privé de 600 000 $ Placement Privé Offre De Titres Mandats Financement Des Entreprises Approbation Réglementaire
COMMUNIQUÉ DE PRESSE publié le 17/04/2025 à 01:30, il y a 1 année Onco-Innovations Announces Private Placement Onco-Innovations Limited announces a non-brokered private placement of up to 400,000 units at $1.50 per unit, for gross proceeds of up to $600,000, with plans for cancer research and treatment advancements Private Placement Securities Oncology Cancer Research Onco-Innovations Limited
Publié le 07/05/2026 à 19:15, il y a 1 jour 15 heures 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 1 jour 15 heures Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 1 jour 15 heures Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 1 jour 15 heures Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 1 jour 15 heures ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 09/05/2026 à 01:30, il y a 9 heures 15 minutes Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 10 heures 45 minutes Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 08/05/2026 à 20:38, il y a 14 heures 7 minutes EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Publié le 08/05/2026 à 19:12, il y a 15 heures 33 minutes EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Publié le 08/05/2026 à 19:02, il y a 15 heures 43 minutes Metall Zug – Annual General Meeting of Shareholders approves all proposals